scorecardresearch Skip to main content

Omicron, now 2 years old, is not done with us yet

In the two years since its emergence, Omicron has proved to be staggeringly infectious and an evolutionary marvel resulting from dozens of mutations. And as Omicron continues to evolve, public health researchers still see a benefit to vaccinations.ADRIANA ZEHBRAUSKAS/NYT

By November 2021, nearly two years after the coronavirus emerged in Wuhan, China, and spread across the world, the surprises seemed to be over. More than 4 billion people had been vaccinated against the virus, and 5 million had died. Two new variants, known as alpha and delta, had surged and then ebbed. As Thanksgiving approached, many Americans were planning to resume traveling for the holiday.

And then, the day after the turkey, the pandemic delivered a big new surprise. Researchers in Botswana and South Africa alerted the world that a highly mutated version of the virus had emerged and was spreading fast. Omicron, as the World Health Organization called the variant, swiftly overtook other forms of the virus. It remains dominant now, on its second anniversary.

Advertisement



In the two years since its emergence, Omicron has proved to be not only staggeringly infectious, but also an evolutionary marvel, challenging many assumptions virologists had before the pandemic. It has given rise to an impressive number of descendants, which have become far more adept at evading immunity and finding new victims.

“It was almost like there was another pandemic,” said Adam Lauring, a virus expert at the University of Michigan.

Lauring and other Omicron watchers are trying to make sense of the past two years in order to prepare for the future. It’s possible that Omicron will become a permanent part of life, steadily mutating like seasonal influenza.

When Omicron first came to light, the United States and other countries wrongly believed they could stop its spread by barring travelers from South Africa. In reality, it had already spread far and wide. In a matter of days, Britain, Italy, and Germany discovered Omicron in positive COVID tests.

Omicron’s gift for spreading fast was the result of dozens of mutations. They altered the virus’ surface, so that antibodies produced by vaccines or previous infections could not stick tightly to it and prevent the virus from invading cells.

Advertisement



“It was the first virus to figure out in a major way how to escape immunity,” said Dr. Jacob Lemieux, an infectious disease specialist at Massachusetts General Hospital.

Lemieux and many other experts suspect that the variant gained its new mutations while infecting a single person with a weak immune system. Immunocompromised people can only fight off some of the coronaviruses during an infection, allowing the ones that remain to acquire mutations that can thwart the immune system.

“It becomes like a laboratory for virus evolution,” said Peter Markov, a virus expert at the London School of Hygiene and Tropical Medicine.

As public health researchers tracked the Omicron wave in late 2021, they saw a crucial difference from earlier surges. Compared with previous variants, Omicron put a smaller fraction of infected people in the hospital. One reason was that so many people had immunity to earlier forms of the coronavirus. Our immune defenses include not just antibodies, but special immune cells that can recognize and kill infected cells. This second line of defense held up even against Omicron, preventing many of the new infections from becoming severe.

Yet, Omicron caused so many new infections — the initial wave infected almost half of all Americans, according to one recent estimate — that it still unleashed a devastating wave of hospitalizations.

The Omicron surge hit the United States and most other countries in early 2022. China managed to hold back the waves with its “zero COVID” policy, but protests against its brutality grew so intense that President Xi Jinping dropped it abruptly in November 2022. The floodgates opened: Within a few weeks, more than 1 billion Chinese people contracted Omicron, resulting in over 1 million deaths.

Advertisement



As Omicron moved from person to person, its descendants gained more mutations. Sometimes, two Omicron viruses would wind up in the same cell, which would produce new hybrid viruses with a mix of their genes. One of these so-called recombinations hit the jackpot by mixing together two sets of evasive mutations. The result was a new hybrid called XBB.

XBB easily infected people and became dominant in the United States in early 2023.

Vaccine makers tried to keep up with Omicron’s rapid evolution. In August 2022, the Food and Drug Administration authorized booster shots that targeted the BA.5 Omicron variant, which was then dominant. In September 2023, the agency authorized an XBB shot. But XBB is now ebbing as a menagerie of even more evasive variants has evolved.

“Right now we’re in a period of chaos,” said Marc Johnson, a virus expert at the University of Missouri.

Several researchers said the chaos might soon end. In August, a variant called BA.2.86 emerged with a host of new mutations — most likely the result, once again, of evolution taking place in an immunocompromised person.

Over the past few months, the BA.2.86 lineage seems to have kicked into high gear, gaining a mutation that allows it to evade even more antibodies. JN.1, as this mutated form is known, has become the most resistant version of the coronavirus. It appears to be growing quickly in France, and may soon spread to other countries.

Advertisement



As Omicron continues to evolve, public health researchers still see a benefit to vaccinations. Justin Lessler, a researcher at the University of North Carolina, and his colleagues recently ran a projection of future COVID infections and concluded that annual vaccination campaigns could save up to 49,000 lives a year.

Those vaccines will be more effective if they’re updated to keep up with the evolving virus. But Katrina Lythgoe, a biologist at Oxford University, worries that their development will slow as governments stop paying for genetic sequencing of new variants.

“If we don’t sequence things, then we won’t see them,” she said.

This article originally appeared in The New York Times.